Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

Pharmacogenetics - 1 Oct 2001

Dai D, Zeldin D C, Blaisdell J A, Chanas B, Coulter S J, Ghanayem B I, Goldstein J A

Abstract excerpt

Cytochrome P450 (CYP) 2C8 is the principal enzyme responsible for the metabolism of the anti-cancer drug paclitaxel (Taxol). It is also the predominant P450 responsible for the metabolism of arachidonic acid to biologically active epoxyeicosatrienoic acids (EETs) in human liver and kidney. In this study, we describe two new CYP2C8 alleles containing coding changes: CYP2C8*2 has an Ile269Phe substitution in exon 5...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Arachidonic Acid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aryl Hydrocarbon Hydroxylases

Share to Cytochrome P-450 CYP2C8

Share to Metabolic Clearance Rate

Share to Paclitaxel

Share to Steroid 16-alpha-Hydroxylase

Share to Steroid Hydroxylases

Source

Identifiers

PMID: 11668219
DOI: 10.1097/00008571-200110000-00006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.PMID 11668219Read ↗

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.Semantic proximity Read ↗

Functional Characterization of Allelic Variations of Human Cytochrome P450 2C8 (V181I, I244V, I331T, and L361F).Semantic proximity Read ↗

The Cytochrome P450 Slow Metabolizers CYP2C9*2 and CYP2C9*3 Directly Regulate Tumorigenesis via Reduced Epoxyeicosatrienoic Acid Production.Semantic proximity Read ↗

Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel.Semantic proximity Read ↗

Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms.Semantic proximity Read ↗

Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation.Semantic proximity Read ↗

Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation.Semantic proximity Read ↗

Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism.Semantic proximity Read ↗

Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions.Semantic proximity Read ↗

Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.Semantic proximity Read ↗

Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population.Semantic proximity Read ↗

CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.